Neurology News

PHILADELPHIA — Diffuse axonal injury-type lesions in postoperative MRI can predict poor outcomes for children with severe traumatic brain injury, a presenter said at the American Association of Neurological Surgeons annual meeting.

Patients with Lennox-Gastaut syndrome experienced a significant reduction in drop seizures with fenfluramine, according to results of a clinical trial published in JAMA Neurology.

The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

The FDA granted breakthrough device designation and permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.

TecTraum Inc. announced complete enrollment status for a clinical trial evaluating its pro2cool device, a noninvasive hypothermic therapy system for treating concussions.

PHILADELPHIA — An endovascular brain-computer interface allowed those who are paralyzed to perform computer-based activities, according to a presenter at the American Association of Neurological Surgeons annual meeting.

In this week’s edition, risk for cognitive decline is associated with older COVID-19 survivors; a study validates an FDA-approved blood test for traumatic brain injury; and more.

The Parkinson’s Foundation has expanded its PD GENEration study, a national initiative that offers no-cost genetic testing and counseling to those with Parkinson’s disease, to 23 actively enrolling participant sites.

Most patients with relapsing-remitting MS who are stable on natalizumab every 4 weeks, can switch to a 6-week dosing regimen without losing efficacy, according to results of a clinical trial published in the Lancet Neurology.

The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.